Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Panitumumab: an arrow on target.

Literature DB >> 20432075

Panitumumab: an arrow on target.

Abstract

Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20432075 DOI： 10.1007/s12253-010-9257-7

Source DB: PubMed Journal: Pathol Oncol Res ISSN： 1219-4956 Impact factor: 3.201

29 in total

1. Cetuximab and panitumumab: are they interchangeable?

Authors: Richard Kim
Journal: Lancet Oncol Date: 2009-10-28 Impact factor: 41.316

2. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors: Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701

3. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Authors: Daniel J Freeman; Todd Juan; Maureen Reiner; J Randolph Hecht; Neal J Meropol; Jordan Berlin; Edith Mitchell; Ildiko Sarosi; Robert Radinsky; Rafael G Amado
Journal: Clin Colorectal Cancer Date: 2008-05 Impact factor: 4.481

4. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.

Authors: Aya Jakobovits; Rafael G Amado; Xiaodong Yang; Lorin Roskos; Gisela Schwab
Journal: Nat Biotechnol Date: 2007-10 Impact factor: 54.908

5. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

Authors: Andrea Sartore-Bianchi; Mauro Moroni; Silvio Veronese; Carlo Carnaghi; Emilio Bajetta; Gabriele Luppi; Alberto Sobrero; Carlo Barone; Stefano Cascinu; Giuseppe Colucci; Enrico Cortesi; Michele Nichelatti; Marcello Gambacorta; Salvatore Siena
Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544

6. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

Authors: Jordan Berlin; James Posey; Simon Tchekmedyian; Eddie Hu; David Chan; Imtiaz Malik; Liqiang Yang; Rafael G Amado; J Randolph Hecht
Journal: Clin Colorectal Cancer Date: 2007-03 Impact factor: 4.481

7. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Authors: Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar
Journal: Clin Cancer Res Date: 2009-04-14 Impact factor: 12.531

8. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544

9. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

Authors: Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher
Journal: J Clin Oncol Date: 2004-06-21 Impact factor: 44.544

10. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors: Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal: N Engl J Med Date: 2009-02-05 Impact factor: 91.245

1 in total

Review 1. Molecularly targeted drugs for metastatic colorectal cancer.

Authors: Ying-dong Cheng; Hua Yang; Guo-qing Chen; Zhi-cao Zhang
Journal: Drug Des Devel Ther Date: 2013-11-01 Impact factor: 4.162

1 in total